Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology (Nasdaq: OLMA) granted stock options to three new employees for an aggregate of 77,000 shares, effective October 1, 2025, approved under the company's 2022 Inducement Plan as required by Nasdaq Listing Rule 5635(c)(4).
The options vest over four years (25% after one year, then 36 equal monthly installments), have a 10-year term, and an exercise price of $11.04 per share (equal to the last reported sale price on Nasdaq on October 1, 2025). Olema disclosed the awards to comply with Nasdaq rules governing inducement grants.
Olema Oncology (Nasdaq: OLMA) ha concesso opzioni su azioni a tre nuovi dipendenti per un ammontare complessivo di 77.000 azioni, valide dal 1 ottobre 2025, approvate ai sensi del Piano di Induzione 2022 della società come richiesto dalla Nasdaq Listing Rule 5635(c)(4).
Le opzioni maturano in quattro anni (il 25% dopo un anno, poi 36 rate mensili uguali), hanno una durata di 10 anni e un prezzo di esercizio di $11.04 per azione (pari all'ultimo prezzo di vendita riportato su Nasdaq il 1 ottobre 2025). Olema ha divulgato le assegnazioni per conformarsi alle norme Nasdaq riguardanti i grant di induzione.
Olema Oncology (Nasdaq: OLMA) concedió opciones sobre acciones a tres nuevos empleados por un total de 77,000 acciones, con efecto a partir del 1 de octubre de 2025, aprobadas bajo el Plan de Inducción 2022 de la empresa, como lo exige la Regla de Listado 5635(c)(4) de Nasdaq.
Las opciones se consolidan en cuatro años (25% tras un año, luego 36 cuotas mensuales iguales), tienen un plazo de 10 años y un precio de ejercicio de $11.04 por acción (igual al último precio de venta reportado en Nasdaq el 1 de octubre de 2025). Olema divulgó las adjudicaciones para cumplir con las normas de Nasdaq que rigen las concesiones por inducimiento.
Olema Oncology (나스닥: OLMA)는 3명의 신규 직원에게 총 77,000주에 해당하는 스톡 옵션을 부여했으며, 효력은 2025년 10월 1일부터 발효되고 회사의 2022년 유도 계획에 따라 나스닥 상장 규칙 5635(c)(4)에 의해 승인되었습니다.
옵션은 4년 동안 베스팅되며(1년 후 25%, 이후 매월 동일한 36회 분할), 만료 기간은 10년, 주당 행사가격은 미화 11.04달러로 설정되어 있습니다(2025년 10월 1일 나스닥에 보고된 마지막 매매가와 동일). Olema는 인듀스먼트 규칙에 따른 나스닥 규정을 준수하기 위해 보상을 공시했습니다.
Olema Oncology (NASDAQ : OLMA) a accordé des options d'achat d'actions à trois nouveaux employés pour un total de 77 000 actions, effectives au 1er octobre 2025, approuvées dans le cadre du Plan d'induction 2022 de la société comme requis par la règle de cotation Nasdaq 5635(c)(4).
Les options s'acquiissent sur quatre ans (25 % après un an, puis 36 versements mensuels égaux), ont une durée de 10 ans et un prix d'exercice de 11,04 $ par action (égal au dernier prix de vente reporté sur Nasdaq au 1er octobre 2025). Olema a divulgué les attributions pour se conformer aux règles de Nasdaq régissant les octrois par induction.
Olema Oncology (Nasdaq: OLMA) hat drei neuen Mitarbeitern insgesamt 77.000 Aktienoptionen gewährt, wirksam ab dem 1. Oktober 2025, genehmigt im Rahmen des Unternehmensplans 2022 Induction Plan gemäß Nasdaq Listing Rule 5635(c)(4).
Die Optionen vesten über vier Jahre (25% nach einem Jahr, dann 36 gleiche monatliche Raten), haben eine Laufzeit von 10 Jahren und einen Ausübungspreis von 11,04 USD pro Aktie (entsprechend dem zuletzt gemeldeten Verkaufspreis an der Nasdaq am 1. Oktober 2025). Olema hat die Zuteilungen offengelegt, um den Nasdaq-Regeln für Induktionszuteilungen zu entsprechen.
Olema Oncology (ناسداك: OLMA) منحت خيارات أسهم لثلاثة موظفين جدد بإجمالي 77,000 سهم، سارية بدءاً من 1 أكتوبر 2025، ومُعتمدة بموجب خطة الحوافز 2022 للشركة كما تقتضي قاعدة إدراج ناسداك 5635(c)(4).
تكون خيارات ممارسة خلال أربع سنوات (25% بعد السنة الأولى، ثم أقساط شهرية متساوية 36 قسطاً)، ولها مدة صلاحية 10 سنوات وسعر تنفيذ قدره $11.04 للسهم (يوازي آخر سعر بيع مُبلغ عنه على ناسداك في 1 أكتوبر 2025). كشفت أولما عن المنح الامتثالية وفقاً لقواعد ناسداك التي تحكم منح الحوافز.
Olema Oncology (纳斯达克：OLMA) 已向三名新员工授予股票期权，总共 77,000 股，生效日期为 2025年10月1日，经公司 2022年引导计划 批准，符合 Nasdaq Listing Rule 5635(c)(4) 的要求。
这些期权在四年内逐步解锁（第一年后解锁 25%，随后按月等额分期 36 次），期限为 10 年，行使价为每股 $11.04（等于 2025 年 10 月 1 日 Nasdaq 的最近成交价）。Olema 披露了该授予，以符合 Nasdaq 关于诱导性授予的规定。
- None.
- None.
SAN FRANCISCO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to three new employees to purchase an aggregate of 77,000 shares of the Company's common stock, effective as of October 1, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
What did Olema (OLMA) announce on October 2, 2025 about employee option grants?
What is the vesting schedule for the OLMA inducement stock options?
What is the exercise price and term of Olema's October 2025 option grants (OLMA)?
Under which plan were Olema's October 2025 options granted (OLMA)?
Why did Olema disclose these option grants on October 2, 2025 (OLMA)?
Do Olema's October 2025 option grants immediately dilute existing shareholders (OLMA)?
